Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Neville (Portsmouth, United Kingdom). Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma. 1585

Member's Comments

No comment yet.

Related content which might interest you: Pleural fluid, serum β-HCG levels and pleural fluid/serum β-HCG ratio for the discrimination of malignant and benign pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003 Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Cytology of pleural fluid versus histopathology of the pleura in the diagnosis of malignant pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 775s Year: 2006 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Pleural fluid leptin level for the differential diagnosis of pleural effusion Source: Eur Respir J 2006; 28: Suppl. 50, 343s Year: 2006 Pleural fluid procalcitonin levels in identifying pleural effusions due to infection Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009 Utility of pleural fluid for predictive marker testing in malignant pleural effusion Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020 Correlation between pleural fluid cytological yield and pleural tumour burden in malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Value of thoracoscopic pleural brush in the diagnosis of exudative pleural effusion Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Evaluation of pleural fluid clot histology in the diagnosis of pleural malignancy Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Malignant pleural effusions: diagnosis and management Source: International Congress 2017 – PG5 Pleural disease management Year: 2017 Malignant pleural effusions: from the diagnosis to the management Source: International Congress 2015 – ME2 Malignant pleural effusions: from diagnosis to management Year: 2015 Management of malignant pleural effusions Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Management of malignant pleural effusions Source: Guideline 2001 Year: 2001 Management of malignant pleural effusions Source: Eur Respir J 2001; 18: 402-419 Year: 2001 Validity of Pleural Fluid Protein in differentiating Tuberculous from Malignant Pleural Effusion Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019